Liver toxicity: The Achilles' heel of endothelin receptor antagonist therapy?

European Respiratory Journal

Volumn 34, Issue 3, 2009, Pages 529-530

  Hoeper, M M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; BILIRUBIN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PHENPROCOUMON; SITAXSENTAN;

AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONVALESCENCE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; EOSINOPHIL; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; SIDE EFFECT;

DRUG-INDUCED LIVER INJURY; HUMANS; ISOXAZOLES; RECEPTORS, ENDOTHELIN; THIOPHENES;

EID: 70349088094     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00094409     Document Type: Editorial

References (9)

1. Hoeper MM, Olsson KM, Schneider A, et al. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009; 33: 1518-1519.
2. Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009; 34: 770-771.
3. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-1868. (Pubitemid 34634407)
4. Schimanski CC, Burg J, Mohler M, et al. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. J Hepatol 2004; 41: 67-74. (Pubitemid 39005155)
5. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-414.
6. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231. (Pubitemid 32382504)
7. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
8. Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007; 26: 63-69. (Pubitemid 46096748)
9. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344. (Pubitemid 47194187)